EDP Sciences logo
Subscriber Authentication Point
Search
Menu
Home All issues Volume 25 / No 11 (Novembre 2009) Med Sci (Paris), 25 11 (2009) 939-944 References
Free Access
Issue
Med Sci (Paris)
Volume 25, Number 11, Novembre 2009
Page(s) 939 - 944
Section M/S revues
DOI https://doi.org/10.1051/medsci/20092511939
Published online 15 November 2009
  1. Livermore DM. Bacterial resistance: origins, epidemiology, and impact. Clin Infect Dis 2003; 36 (suppl 1) : S11–23. [Google Scholar]
  2. Schwaber MJ, Carmeli Y. Mortality and delay in effective therapy associated with extended-spectrum beta-lactamase production in Enterobacteriaceae bacteraemia: a systematic review and meta-analysis. J Antimicrob Chemother 2007; 60 : 913–20. [Google Scholar]
  3. Jacoby GA, Munoz-Price LS. The new beta-lactamases. N Engl J Med 2005; 352 : 380–91. [Google Scholar]
  4. Knothe H, Shah P, Krcmery V, et al. Transferable resistance to cefotaxime, cefoxitin, cefamandole and cefuroxime in clinical isolates of Klebsiella pneumoniae and Serratia marcescens. Infection 1983; 11 : 315–7. [Google Scholar]
  5. Lucet JC, Decré D, Fichelle A, et al. Control of a prolonged outbreak of extended-spectrum beta-lactamase-producing enterobacteriaceae in a university hospital. Clin Infect Dis 1999; 29 : 1411–8. [Google Scholar]
  6. Paterson DL, Bonomo RA. Extended-spectrum beta-lactamases: a clinical update. Clin Microbiol Rev 2005; 18 : 657–86. [Google Scholar]
  7. Nicolas-Chanoine MH, Jarlier V, et al. Extended-spectrum beta-lactamases in long-term-care facilities. Clin Microbiol Infect 2008; 14 (suppl 1) : 111–6. [Google Scholar]
  8. http://www.cclinparisnord.org/BMR/2007/Rapport_BMR2007.pdf. [Google Scholar]
  9. Lucet JC, Paoletti X, Lolom I, et al. Successful long-term program for controlling methicillin-resistant Staphylococcus aureus in intensive care units. Intensive Care Med 2005; 31 : 1051–7. [Google Scholar]
  10. Pitout JD, Laupland KB. Extended-spectrum beta-lactamase-producing Enterobacteriaceae: an emerging public-health concern. Lancet Infect Dis 2008; 8 : 159–66. [Google Scholar]
  11. Hawkey PM. Prevalence and clonality of extended-spectrum beta-lactamases in Asia. Clin Microbiol Infect 2008; 14 (suppl 1) : 159–65. [Google Scholar]
  12. Livermore DM, Canton R, Gniadkowski M, et al. CTX-M: changing the face of ESBL in Europe. J Antimicrob Chemother 2007; 59 : 165–74. [Google Scholar]
  13. Valverde A, Coque TM, Sánchez-Moreno MP, et al. Dramatic increase in prevalence of fecal carriage of extended-spectrum beta-lactamase-producing Enterobacteriaceae during nonoutbreak situations in Spain. J Clin Microbiol 2004; 42 : 4769–75. [Google Scholar]
  14. Ben-Ami R, Schwaber MJ, Navon-Venezia S, et al. Influx of extended-spectrum beta-lactamase-producing enterobacteriaceae into the hospital. Clin Infect Dis 2006; 42 : 925–34. [Google Scholar]
  15. Kader AA, Kumar A, Kamath KA. Fecal carriage of extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in patients and asymptomatic healthy individuals. Infect Control Hosp Epidemiol 2007; 28 : 1114–6. [Google Scholar]
  16. Goldstein FW. Antibiotic susceptibility of bacterial strains isolated from patients with community-acquired urinary tract infections in France. Multicentre Study Group. Eur J Clin Microbiol Infect Dis 2000; 19 : 112–7. [Google Scholar]
  17. Grobost F. Épidémiologie des entérobactéries productrices deβ-lactamase à spectre élargi (EBLSE communautaires en France : enquête transréseaux dans les laboratoires de ville). Paris, France : 26e RICAI, réunion interdisciplinaire de chimiothérapie anti-infectieuse, 2006 (abstract). [Google Scholar]
  18. Colodner R, Rock W, Chazan B, et al. Risk factors for the development of extended-spectrum beta-lactamase-producing bacteria in nonhospitalized patients. Eur J Clin Microbiol Infect Dis 2004; 23 : 163–7. [Google Scholar]
  19. Calbo E, Romaní V, Xercavins M, et al. Risk factors for community-onset urinary tract infections due to Escherichia coli harbouring extended-spectrum beta-lactamases. J Antimicrob Chemother 2006; 57 : 780–3. [Google Scholar]
  20. Rodríguez-Baño J, Navarro MD, Romero L, et al. Clinical and molecular epidemiology of extended-spectrum beta-lactamase-producing Escherichia coli as a cause of nosocomial infection or colonization: implications for control. Clin Infect Dis 2006; 42 : 37–45. [Google Scholar]
  21. Rodríguez-Baño J, Navarro MD, Romero L, et al. Risk-factors for emerging bloodstream infections caused by extended-spectrum beta-lactamase-producing Escherichia coli. Clin Microbiol Infect 2008; 14 : 180–3. [Google Scholar]
  22. Harris AD, McGregor JC, Johnson JA, et al. Risk factors for colonization with extended-spectrum beta-lactamase-producing bacteria and intensive care unit admission. Emerg Infect Dis 2007; 13 : 1144–9. [Google Scholar]
  23. Lavigne JP, Marchandin H, Delmas J, et al. CTX-M beta-lactamase-producing Escherichia coli in French hospitals: prevalence, molecular epidemiology, and risk factors. J Clin Microbiol 2007; 45 : 620–6. [Google Scholar]
  24. Valverde A, Grill F, Coque TM, et al. High rate of intestinal colonization with extended-spectrum-beta-lactamase-producing organisms in household contacts of infected community patients. J Clin Microbiol 2008; 46 : 2796–9. [Google Scholar]
  25. Laupland KB, Church DL, Vidakovich J, et al. Community-onset extended-spectrum beta-lactamase (ESBL) producing Escherichia coli: importance of international travel. J Infect 2008; 57 : 441–8. [Google Scholar]
  26. Reddy P, Malczynski M, Obias A, et al. Screening for extended-spectrum beta-lactamase-producing Enterobacteriaceae among high-risk patients and rates of subsequent bacteremia. Clin Infect Dis 2007; 45 : 846–52. [Google Scholar]
  27. Glupczynski Y, Huang TD, Berhin C, et al. In vitro activity of temocillin against prevalent extended-spectrum beta-lactamases producing enterobacteriaceae from Belgian intensive care units. Eur J Clin Microbiol Infect Dis 2007; 26 : 777–83. [Google Scholar]
  28. Livermore DM, Tulkens PM. Temocillin revived. J Antimicrob Chemother 2009; 63 : 243–5. [Google Scholar]
  29. Thomas K, Weinbren MJ, Warner M, et al. Activity of mecillinam against ESBL producers in vitro. J Antimicrob Chemother 2006; 57 : 367–8. [Google Scholar]
  30. Zahar JR, Lortholary O, Martin C, et al. Addressing the challenge of extended-spectrum beta-lactamases. Curr Opin Investig Drugs 2009; 10 : 172–80. [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.